STOXPO
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
STOXPO
No Result
View All Result
Home Healthcare Biotechnology

Viking Therapeutics Reports Positive VK2735 Maintenance Data as Obesity Drug Advances

byLiliana Vida
September 22, 2026
in Biotechnology, Mid-Cap
Reading Time: 2 mins read
Share on TwitterShare on LinkedIn

GLP-1/GIP candidate delivers 22% placebo-adjusted weight loss while less-frequent dosing shows potential for maintaining results

Viking Therapeutics (VKTX) announced positive topline results Tuesday from a maintenance study evaluating its experimental obesity drug VK2735, highlighting the potential for multiple dosing schedules designed to help patients maintain weight loss.

The Phase 1 study evaluated VK2735, a dual GLP-1/GIP receptor agonist, across weekly, every-other-week and monthly maintenance regimens following an initial treatment period.

Patients receiving a 17.5 mg weekly dose achieved approximately 22% placebo-adjusted weight loss at Week 33, with no plateau in weight reduction observed. Importantly, participants transitioned to every-other-week dosing maintained up to 97% of their prior weight loss over three months.

The findings suggest VK2735 could potentially offer patients greater flexibility after reaching their weight-loss goals, including less frequent injections. Such dosing options could become important in the competitive obesity-treatment market, where long-term adherence remains a major consideration.

VK2735 is already Viking’s most advanced clinical candidate. The company’s Phase 3 VANQUISH-1 and VANQUISH-2 trials evaluating the injectable formulation in obesity are fully enrolled and progressing.

Viking is also developing an oral version of VK2735, with Phase 3 development expected to broaden the company’s approach to the rapidly expanding obesity market.

The latest maintenance data further strengthen Viking’s case that VK2735 could eventually provide patients with multiple options for both achieving and sustaining significant weight loss.

Tags: GrowthMoversNewsStock MarketVKTX
Previous Post

Top Movers Today:

Next Post

IonQ Shares Rise After Breakthrough in Real-Time Quantum Error Correction

Related Posts

chemistry-2

SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results

byLiliana Vida
November 17, 2026
0

Pivotal REGAL trial demonstrates significant survival benefits, positioning the company for a potential FDA submission in 2027. SELLAS Life Sciences...

D-Wave Quantum Q3 Revenue Climbs 21% as Backlog Surges Over 1,200%

byLiliana Vida
November 11, 2026
0

Quantum computing company reports $4.5 million in revenue, strong year-to-date bookings, and potential access to $100 million in federal funding....

investing

D-Wave Quantum Q3 Revenue Rises 21% as Bookings Surge and Quantum Adoption Expands

byLuca Blaumann
November 10, 2026
0

Quantum computing company beats earnings expectations, reports $503 million in liquidity, and advances major technology initiatives across global markets. D-Wave...

Next Post
ai

IonQ Shares Rise After Breakthrough in Real-Time Quantum Error Correction

Latest News

Anthropic Leveraged ETFs: What GraniteShares’ AIL and ANS Offer Traders

KULR Technology Secures $14.8 Million Purchase Order for Advanced Energy Storage Systems

SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results

Qualcomm CEO Rejects AI Market Correction Fears as Company Expands Into Data Centers

D-Wave Quantum Q3 Revenue Climbs 21% as Backlog Surges Over 1,200%

Based on Your Interest

Artificial Intelligence

CoreWeave Q3 Revenue Surges Nearly 170% to $3.66 Billion as AI Demand Accelerates

November 11, 2026
Artificial Intelligence

CoreWeave Earnings Preview: Why Guidance Matters More Than Q3 Results

November 10, 2026
investing
Artificial Intelligence

D-Wave Quantum Q3 Revenue Rises 21% as Bookings Surge and Quantum Adoption Expands

November 10, 2026

Recommended

Auto Manufacturers

Lucid Secures $1.75 Billion Liquidity Boost From Saudi PIF to Support Turnaround

November 10, 2026
Artificial Intelligence

KULR Technology Revenue Surges 197% in Q3 as Battery Sales Nearly Quadruple

November 10, 2026
Aerospace & Defense

Rocket Lab Q3 Revenue Surges 73% to $268 Million, Beating Wall Street Expectations

November 9, 2026
Artificial Intelligence

IonQ Shares Climb as Company Expands Government Reach Through Carahsoft Partnership

November 9, 2026
Aerospace & Defense

AST SpaceMobile and Rakuten Launch Joint Venture Backed by $1 Billion in Japanese Government Funding

November 9, 2026
Stoxpo

Follow us on social media:

Highlights

  • Anthropic Leveraged ETFs: What GraniteShares’ AIL and ANS Offer Traders
  • KULR Technology Secures $14.8 Million Purchase Order for Advanced Energy Storage Systems
  • SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results
  • Qualcomm CEO Rejects AI Market Correction Fears as Company Expands Into Data Centers
  • D-Wave Quantum Q3 Revenue Climbs 21% as Backlog Surges Over 1,200%

Category

  • Blog
  • Communication Services
    • Entertainment
    • Internet
    • Telecommunications
  • Companies
    • Large-Cap
    • Mega-Cap
    • Micro-Cap
    • Mid-Cap
    • Small-Cap
  • Consumer Cyclical
    • Auto Manufacturers
    • Casinos & Gambling
    • Ground Transportation
    • Hospitality
      • Casinp
      • Resorts & Lodging
      • Restaurants
      • Travel
        • Airlines
    • Retail
    • Textiles, Apparel & Luxury Goods
  • Consumer Defensive
    • Beverages
    • Discount Stores
    • Distributor
    • Ecommerece
    • Electrical Equipment
    • Foods
    • Household & Personal Products
    • Leisure Products
    • Tobacco
  • Contributions
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Economy
  • Energy
    • Electric
    • Oil & Gas
    • Renewables
  • Financial Services
    • Asset Management
    • Banks
    • Brokerages
    • Credit Services
    • Insurance
  • Healthcare
    • Biotechnology
    • Medical Devices
    • Pharmaceuticals
  • Industrials
    • Aerospace & Defense
    • Construction
    • Industrial Machinery
  • Materials
    • Building Materials
    • Chemicals
    • Gold
    • Mining
    • Silver
    • Steel
  • Q&A's
  • Real Estate
  • Technology
    • Artificial Intelligence
    • Computer Hardware
    • Consumer Electronics
    • Cybersecurity
    • IT Services
    • Semiconductors
    • Software
  • Utilities

Latest News

Anthropic Leveraged ETFs: What GraniteShares’ AIL and ANS Offer Traders

November 20, 2026

KULR Technology Secures $14.8 Million Purchase Order for Advanced Energy Storage Systems

November 18, 2026
chemistry-2

SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results

November 17, 2026
  • About
  • Privacy Policy
  • Contact

© 2024 All Rights Reserved: STOXPO.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More

In case of sale of your personal information, you may opt out by using the link Do Not Sell My Personal Information

Accept Cookie Settings
Cookies are small text files that can be used by websites to make a user's experience more efficient. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission. This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
  • Always Active
    Necessary
    Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
  • Marketing
    Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
  • Analytics
    Analytics cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
  • Preferences
    Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
  • Unclassified
    Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
Cookie Settings

Do you really wish to opt-out?

No Result
View All Result
  • Latest News
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Technology
    • Software
    • Semiconductors
  • Crypto
    • Bitcoin
    • Ethereum
    • Altcoins
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions

© 2024 All Rights Reserved: STOXPO.